Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04714320 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure
A Phase 2 study of Hypertension, sponsored by Ionis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 20
- Study locations
NCT04714320: Completed Phase 2 study of Hypertension, sponsored by Ionis Pharmaceuticals.
NCT04714320 is a Phase 2 study of Hypertension that has completed, run by Ionis Pharmaceuticals. The registered enrollment target is 160 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04714320, a Phase 2 study of Hypertension, has completed, sponsored by Ionis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study was to evaluate the effect of IONIS-AGT-LRx compared to placebo on seated automated office systolic blood pressure (SBP) from baseline to Study Day 85 in uncontrolled hypertensive participants on ≥ 3 antihypertensive medications and to evaluate the effect of IONIS-AGT-LRx on ambulatory blood pressure, seated automated office SBP, seated automated office diastolic blood pressure (DBP), and plasma angiotensinogen (AGT) at each scheduled visit in uncontrolled hypertensive participants on ≥ 3 antihypertensive medications.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG IONIS-AGT-LRx
Study Locations (20)
California
- Advanced Research Center - Anaheim
- National Research Institute - Huntington Park - Huntington Park
- RESPIRE Research - La Mesa
- Clinical Trials Research - Lincoln
- Catalina Research Institute - Montclair
- San Fernando Valley Health Institute - Van Nuys
Florida
- ALL Medical Research, LLC - Cooper City
- Nature Coast Clinical Research - Crystal River - Crystal River
- East Coast Institute for Research - Jacksonville
- Canvas Clinical Research - Lake Worth
- Allied Biomedical Research Institute, Inc. - Miami
- AMPM Research Clinic - Miami Gardens
Alabama
- Pinnacle Research Group - Anniston
- Central Research Associates, Inc. - Birmingham
- Achieve Clinical Research, LLC - Birmingham
- Cahaba Research, Inc. - Pelham
- Syed Research Consultants LLC - Sheffield
Arkansas
- Cardiology and Medicine Clinic - Little Rock
Colorado
- Creekside Endocrine Associates, PC - Denver
Connecticut
- Chase Medical Research LLC - Waterbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2021-04-28 |
| Est. Completion | 2022-10-03 |
| Phase | Phase 2 |
What the finished NCT04714320 record still lists
NCT04714320 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04714320 names 20 study sites across 6 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT04714320 about?
NCT04714320 is a clinical study titled "A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure". The purpose of this study was to evaluate the effect of IONIS-AGT-LRx compared to placebo on seated automated office systolic blood pressure (SBP) from baseline to Study Day 85 in uncontrolled hypertensive participants on ≥ 3 antihypertensive medications and to evaluate the effect of IONIS-AGT-LRx o...
What is the current status of trial NCT04714320?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2021-04-28. Estimated completion is 2022-10-03.
What conditions does trial NCT04714320 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT04714320?
The interventions under investigation include: Placebo (DRUG), IONIS-AGT-LRx (DRUG).
Who is sponsoring clinical trial NCT04714320?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04714320 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04714320's enrollment target sits among peer trials
160 238th of 470 higher than 228 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
RECRUITING · Phase 2
-
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
RECRUITING · Phase 2
-
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
RECRUITING · Phase 2
-
Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)
RECRUITING · Phase 2
-
PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis
RECRUITING · Phase 2
-
Virtual Diabetes Group Visits Across Health Systems
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
- NCT02193841 · 160 participants · Phase 3
Simple Bone Cysts in Kids
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI